Comprehensive mCSPC Management for Urologists: Debunking Myths, Optimizing Outcomes, and Supporting Patient-Centered Intensification
Type
Webinar
EVENT DETAILS
Display Date
Wednesday, March 26, 2025
Display Date Line 2
19:00 ET
Location
Virtual
Speaker
Scott Edwards, Avril Lusty & Ricardo Rendon
ACCREDITATION
Accreditation
Section 1 Group Learning Credits
Event Description
Speakers: Scott Edwards, Avril Lusty & Ricardo Rendon
Objectives
By participating in this learning program, healthcare providers can expect to:
- Understand the Unique DDI Profiles of ARPIs: Recognize the distinct DDI characteristics among ARPIs and their relevance to common medications in urology, applying this knowledge to optimize treatment selection in mCSPC.
- Interpret Efficacy Endpoints: Apply key efficacy markers, such as ultra-low PSA levels and clinical outcomes, in treatment decision-making, reinforcing the relevance of these endpoints for long-term success regardless of disease volume.
- Balance Safety and QoL: Analyze safety and adverse event data, with a focus on trial methodologies and patient-reported outcomes, to make informed treatment choices that support both efficacy and QoL in mCSPC patients.
- Collaborate for Optimal Patient Care: Engage effectively with pharmacy teams to manage DDIs proactively, leveraging tools like DDI reference guides (Drugapp.ca) and AE checklists to streamline care and mitigate risks associated with polypharmacy.
Footer
ACCREDITATION
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.
_______________________________________________________________________
